Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs
Wei Gao1, Jiang Liu2, Cynthia J Musante3
1EMD Serono, Research & Development Institute, Inc., Billerica, Massachusetts, USA.
Clinical Pharmacology and Therapeutics
|June 5, 2025
Summary
Optimizing oncology drug dosages for new combinations or indications is complex. Quantitative, model-informed approaches are crucial for selecting effective and safe dosing strategies in cancer therapy.
Area of Science:
- Pharmacology
- Oncology
- Clinical Trial Design
Background:
- Current oncology drug dosage optimization primarily targets initial indications.
- Optimizing dosages for combination therapies or subsequent indications presents unique challenges due to altered dose-response relationships.
- Existing evidence and trial designs may not adequately address these complexities.
Purpose of the Study:
- To discuss the complexities of optimizing oncology drug dosages for new combinations and subsequent indications.
- To explore the role of quantitative and model-informed approaches in addressing these challenges.
- To foster dialogue on developing investigational and approved oncology drugs for new therapeutic contexts.
Main Methods:
- A workshop co-sponsored by the US Food and Drug Administration's Office of Clinical Pharmacology and the International Society of Pharmacometrics.
- Discussion focused on model-informed approaches for dose finding, selection, and trial design.
- Consideration of dose-response (DR) and exposure-response (ER) relationships in varied clinical scenarios.
Main Results:
- Identified the need for advanced strategies beyond initial indication optimization.
- Highlighted the impact of combination therapies and subsequent indications on drug efficacy and safety.
- Emphasized the utility of quantitative pharmacology and pharmacometrics.
Conclusions:
- Model-informed approaches are essential for optimizing oncology drug dosages in complex scenarios.
- Further research and discussion are warranted to refine these quantitative strategies.
- Collaboration between regulatory bodies and scientific societies is key to advancing oncology drug development.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.4K
12:08Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
19.5K
Related Concept Videos
01:28Dosage Regimens: Designs and Approaches
266
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
266
01:23Dosage Regimen Designs: Nomograms and Tabulations
184
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
184
01:24Dosage Regimen: Individualization
167
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
167
01:21Dose Size and Dosing Frequency: Determination Methods
279
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
279
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
155
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
155
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
224
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
224